Recombinant OXA peptide (O6012, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in saline to form the solutions with the concentration of 200 ng/μl (high dose), 60 ng/μl (medium dose), and 20 ng/μl (low dose), respectively [10 (link)]. The OXA drug solution was administered intranasally (i.n.) [21 (link)] 1 h after ICH induction, with 2.5 μl in each nostril (5.0 μl per mouse). The same volume (5.0 μl) of saline was administered in the vehicle group of OXA. CaMKKβ inhibitor, STO-609 (S8274, Selleck Chem, Houston, TX, USA), was dissolved in 5% dimethyl sulfoxide (DMSO) to yield a drug solution with a concentration of 5 mg/ml, and 100 μl of the drug solution was injected intraperitoneally (i.p.) 1 h after ICH induction [22 (link)]. SB-334867 (S7585, Selleck Chem, Houston, TX, USA) [23 (link), 24 (link)] or JNJ-10397049 (sc-491320, Santa Cruz, Dallas, TX, USA) [25 (link)], which is respectively OXR1 or OXR2 selective antagonist, was dissolve in 5% DMSO to form the drug solution (10 mg/ml), and then 100 μl was injected (i.p.) 1 h after ICH induction. The vehicle group received the same volume (100 μl) of 5% DMSO.
Sb 334867
Manufactured by Selleck Chemicals
Sourced in United States
SB-334867 is a chemical compound used in laboratory settings. It is a selective antagonist for the orexin 2 receptor (OX2R), which is involved in the regulation of sleep-wake cycles. The compound can be used in research applications to study the role of the orexin system in physiological and behavioral processes.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using sb 334867
1
Intranasal Orexin-A Treatment for ICH
2
Orexin Receptor Antagonists and Neuronal Viability
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Hippocampal neurons were planted in 96-well plates (Corning, Corning, USA) for 24 h. Different reagents were added to cells for 24 h or 48 h. SB334867, an OX1 receptor (OX1R) antagonist [19 (link)], was obtained from Selleck Chemicals (Houston, TX, USA). TCSOX229, the OX2 receptor (OX2R) antagonist [20 (link),21 (link)], and orexin-A were purchased from MCE (NJ, USA). NU1025, an inhibitor of PARP [22 (link)], was obtained from Selleck Chemicals (Houston, TX, USA). The CCK-8 kit (Invitrogen, Carlsbad, CA, USA) mixed with free FBS DMEM/F-12 medium (Gibco, Carlsbad, CA, USA) was added to the wells after discarding medium. The plates were read using a microplate reader (Thermo, Waltham, MA, USA) at the wavelength of 490 nm.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!